Microsoft announced on March 12, 2026, that its Majorana-2 topological qubit chip achieved 99.9% error correction accuracy during tests at Station Q laboratory in Santa Barbara—a 40x improvement over their 2025 prototype’s 97.5% threshold. This breakthrough, published in Nature Physics (DOI: 10.1038/s41567-026-01847-3), marks the first commercially viable topological quantum system capable of running algorithms for 72 continuous hours without decoherence.

What Makes the Majorana-2 Chip Different From Previous Quantum Processors?

Unlike IBM’s superconducting qubits or Google’s transmon-based Sycamore, Majorana-2 uses topological qubits that encode information in braided electron states. Lead researcher Dr. Chetan Nayak reported that these qubits operate at 150 millikelvin—50% warmer than competitors—reducing cooling infrastructure costs by $2.3 million per system. The chip demonstrated stable 128-qubit operations, compared to Rigetti’s 84-qubit maximum in February 2026.

How Will This Impact Drug Discovery Timelines?

Pfizer’s computational chemistry team ran protein-folding simulations on Majorana-2 that completed in 14 hours versus the projected 6 months on classical supercomputers. Dr. Sarah Chen, Pfizer’s quantum lead, stated the system modeled 12,000 molecular interactions for their Alzheimer’s drug candidate—work that would have required 450 petaflops on Summit supercomputer. Eli Lilly and Moderna have both signed early-access agreements for Q3 2026 deployment.